|

Tumor Treating Fields Win FDA Approval for Mesothelioma Treatment

ByAlex Strauss
Tumor Treating Fields mesothelioma treatment

The FDA has approved an electricity-based mesothelioma treatment known as Tumor Treating Fields (NovoTTF-100L). The treatment is approved for use along with standard mesothelioma chemotherapy. It is the first new treatment for pleural mesothelioma since the approval of Alimta (pemetrexed) in 2004.

Approval of NovoTTF-100L was based on the promising results of the STELLAR phase 2 mesothelioma clinical trial. Those results, released in April, were even better than expected.

Electricity is the Basis of Tumor Treating Fields

The Tumor Treating Fields approach was created by Jersey-based Novocure. It first found success in the treatment of the deadly brain cancer glioblastoma.

The technology uses electrical fields to destabilize critical proteins responsible for cell division.

When these proteins cannot do their job, mesothelioma cells cannot divide. Preclinical data showed that mesothelioma cells are especially sensitive to Tumor Treating Fields.

Combination Treatment Extends Mesothelioma Survival

The STELLAR study included 80 patients with unresectable pleural mesothelioma. They received Tumor Treating Fields along with standard chemotherapy. Researchers compared their results with data on mesothelioma patients who received only chemotherapy.

Patients who had the combination treatment had a median overall survival of more than a year-and-a-half. That is six months longer than mesothelioma patients treated with chemotherapy alone. For patients with epithelial mesothelioma, overall survival was 21.2 months.

A full 97 percent of NovoTTF-100L patients achieved some level of disease control. It took a median of 7.6 months for their mesothelioma tumors to start growing again, compared to just 5.7 months for the chemotherapy-only group.

The technology did not appear to cause any serious side effects. Based on these findings, the FDA granted the NovoTTF-100L technology Humanitarian Use Designation in 2017.

“Since 2000, we have been developing and commercializing Tumor Treating Fields to extend survivals in some of the most aggressive forms of cancer,” says Bill Doyle, executive chairman of Novocure. “FDA approval of NovoTTF-100L provides patients with the first FDA-approved treatment for MPM in more than 15 years and, as our first FDA-approved torso cancer indication, marks a major milestone for Novocure.”

Tumor Treating Fields a New Standard of Care?

Pleural mesothelioma is resistant to conventional cancer treatments. Even though most mesothelioma patients receive chemotherapy, many of them do not get much benefit from it.

Tumor Treating Fields could change that. STELLAR trial investigator Oncologist Giovanni Luca Ceresoli, MD, sees great promise in the technology.

“I believe Tumor Treating Fields represent an extremely promising therapeutic option that, if approved, should be added to standard of care chemotherapy for the treatment of malignant pleural mesothelioma,” he said in a news release last year.

Mesothelioma patients with implanted devices like pacemakers or defibrillators are not candidates for this treatment. Only providers who are trained and certified by Novocure can offer it.

Source:

“FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma”, May 23, 2019, News Release, Novocure Website, https://www.novocure.com/fda-approves-the-novottf-100ltm-system-in-combination-with-chemotherapy-for-the-treatment-of-malignant-pleural-mesothelioma/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…